New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
|Articles|December 1, 2014
- Winter 2014
- Volume 13
- Issue 4
Harmony Hill Retreat Center
Author(s)Elizabeth Whittington
Harmony Hill Retreat Center in Union, Wash., hosts several three-day cancer retreats throughout the year.
Advertisement
Harmony Hill Retreat Center in Union, Wash., hosts several three-day cancer retreats throughout the year. The first session of 2015 will occur Jan. 6-8. The retreats feature daily support groups, drumming, yoga, guided imagery and other activities, in addition to whole-foods meals. Caregivers are welcome to attend. Harmony Hill also offers retreats specifically for women, couples, families and other special groups. While registration, lodging and meals are free, individuals are asked to register in advance on a first-come, first-served basis. For more details, visit harmonyhill.org.
Articles in this issue
almost 12 years ago
TheAnswertoCancer.orgalmost 12 years ago
A Breast Cancer Alphabetalmost 12 years ago
Updates from the European Society for Medical Oncologyalmost 12 years ago
Primary Care After Cancer Treatmentalmost 12 years ago
Adult Female Survivors at Risk for Sexual Issuesalmost 12 years ago
Yoga's Benefits Exploredalmost 12 years ago
Cancer Center Fundraiser was de la Renta's Farewellalmost 12 years ago
Sunshine Act Sheds Light on Gifts to Doctors From Pharmaceutical Companiesalmost 12 years ago
Few Aware that Dense Breasts Increase Cancer Riskalmost 12 years ago
CURE Magazine and curetoday.com Are Under New ManagementAdvertisement
Related to this article
Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
Dr. Morana Vojnic answers common questions about brain cancer, including diagnosis, tumor types, treatment effects, recurrence and life after treatment begins.
A national survey study of about 200,000 adults, published in Supportive Care in Cancer, found that people caring for someone with cancer had 89% higher odds of frequent mental distress than people who were not caregivers.
Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
Dr. Jacqueline Barrientos shares how a targeted therapy, a determined care team and a stranger’s generosity gave a 72-year-old man with hairy cell leukemia and kidney failure a second chance.
A clinical trial will test zanubrutinib plus sonrotoclax as a fixed-duration, chemotherapy-free treatment for hairy cell leukemia, aiming for undetectable disease.
Ronald Chin reflects on hospitality, setting boundaries and accepting his body, and how his greatest strengths and struggles both come from one open heart.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
4 Lung Cancer Results From ESMO 2026 Patients Should Know
5